SMC announced that Enyo Pharma SA presented results of a study using STAM™ model at poster presentation at AASLD The Liver Meeting® 2019 in Boston, MA, November 8-12, 2019.

Title: “In vitro and in vivo characterization of EYP001 a novel, potent and selective FXR agonist now in a phase 2 clinical trial in NASH”